LEGAL INFORMATION

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

The information provided on this site includes information which are “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Company’s strategic focus and the future development and commercialization (by Celldex and others) of rindopepimut (CDX-110), CDX-011, CDX-1135, CDX-1401, CDX-1127, CDX-301, Belinostat and other products. These forward-looking statements are subject to a variety of risks and uncertainties and reflect Celldex's current knowledge, assumptions, judgment and expectations regarding future events and financial performance. You can identify forward-looking statements by the use of the words "may," "will," "can," "anticipate," "assume," "should," "indicate," "would," "believe," "comtemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target," "potential," and other similar words and expressions which predict or indicate future events and trends to and which do not relate to historical matters. You should not rely on forward-looking statements, because they involve known and unknown risks, uncertainties and other factors, some of which are beyond the control of the Company. These risks, uncertainties and other factors may cause the actual results, performance or achievements of the Company to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements.

Some of the factors that might cause these differences include, but are not limited to: (1) our limited cash reserves and our ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; (2) the ability to adopt Celldex’s APC Targeting Technology™ to develop new, safe and effective vaccines against oncology and infectious disease indications; (3) the ability to successfully complete product research and further development, including animal, preclinical and clinical studies, and commercialization of rindopepimut (CDX-110), CDX-1401, CDX-011, CDX-1135, CDX-1127, CDX-301 and other products and Celldex’s expectations regarding market growth for those drug candidates; (4) our ability to manage multiple clinical trials for a variety of drug candidates at different stages of development, including our Phase 3 trial for rindopepimut; (5) the cost, timing, scope and results of ongoing safety and efficacy trials of rindopepimut (CDX-110), CDX-1401, CDX-011, CDX-1135, CDX-1127, CDX-301 and other preclinical and clinical testing; (6) our ability to fund and complete the development and commercialization of rindopepimut for North America internally and to find a strategic partner to commercialize rindopepimut outside of North America; (7) the ability to negotiate strategic partnerships, where appropriate, for our lead programs, including CDX-011 and CDX-1127, as well as for our non-core programs; (8) the strategies and business plans of our partners, such as GlaxoSmithKline’s plans with respect to Rotarix® and Vaccine Technologies’ plans concerning the CholeraGarde® (Peru-15) and ETEC E. coli vaccines, which are not within our control, and our ability to maintain strong, mutually beneficial relationships with these partners; (9) Celldex’s expectations regarding its technological capabilities and expanding its focus to broader markets for vaccines; (10) the availability, cost, delivery and quality of clinical and commercial grade materials produced at Celldex’s own manufacturing facility or supplied by contract manufacturers and partners; (11) changes in existing and potential relationships with corporate collaborators; (12) the availability, cost, delivery and quality of clinical management services provided by our clinical research organization partners; (13) the timing, cost and uncertainty of obtaining regulatory approvals for our product candidates; (14) Celldex’s ability to develop and commercialize products before competitors that are superior to the alternatives developed by such competitors; (15) Celldex’s ability to retain certain members of management; (16) Celldex’s expectations regarding research and development expenses and general and administrative expenses; (17) Celldex’s expectations regarding cash balances, capital requirements, anticipated royalty payments (including those from Paul Royalty Fund), revenues and expenses, including infrastructure expenses; (18) the ability to obtain substantial additional funding; (19) Celldex’s belief regarding the validity of our patents and our ability to avoid potential intellectual property litigation, which can be costly and divert management time and attention; and (20) certain other factors that might cause Celldex’s actual results to differ materially from those in the forward-looking statements including those set forth under the headings “Business, Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations” in each of Celldex’s Annual Report on Form 10-K, its current Reports on Form 8-K, as well as those described in Celldex’s other press releases and filings with the Securities and Exchange Commission, from time to time. You should carefully review all of these factors, and you should be aware that there may be other factors that could cause these differences.

This site contains information concerning Celldex that may be useful to our suppliers, employees and shareholders as well as the general public. Celldex makes no representations or warranties as to the accuracy of the information contained on the site. Further, Celldex expressly disclaims any duty to do so. Celldex assumes no liability or responsibility for any errors or omissions in the content of the site or to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

Terms of Use

By using this World Wide Web (Internet) site, you signify your assent to the terms of use described herein. If you do not agree to these terms, please do not use the site. Celldex Therapeutics, Inc. ("Celldex") reserves the right, at its sole discretion, to change, modify, add, or remove portions of these terms at any time. Please check these terms periodically for changes. Your continued use of this site following the posting of changes to these terms will mean you accept such changes.

All content of this website is owned or controlled by Celldex and is protected by worldwide copyright laws. The trademarks, service marks, trade names, trade dress, and products in this website are protected in the United States and internationally. No use of any of these may be made without the prior written authorization of Celldex, except to identify the products or services of Celldex or to the extent that such use is expressly authorized by law. You may download content only for your personal use for non-commercial purposes, but no modification or further reproduction of the content is permitted. The content may otherwise not be copied or used in any way.

Celldex will use reasonable efforts to keep information in this site current and accurate, but makes no representations, warranties, or assurances as to the accuracy, currency, or completeness of the information provided. Celldex shall not be liable for any damages or injury resulting from anyone's ability or inability to access this site or from anyone's reliance on any information provided at this site. Hyperlinks and references to other sites contained in this site are provided only as a convenience to the users of this site. Celldex makes no representations, warranties, or assurances as to its knowledge of the contents of such sites or the accuracy, currency or completeness of information provided therein. Celldex shall not assume any responsibility for information obtained through hyperlinks or references to other sites contained in this site and shall not be liable for any damages or injury arising from the content of such sites.

Should you provide any information to this website or to Celldex including, without limitation, questions, comments, suggestions or the like regarding the content of this website or any other information relating to Celldex or its technology, such information shall be deemed to be non-confidential and Celldex shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose and distribute the information to others without limitation. Celldex shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including, but not limited to, developing, manufacturing and/or marketing products or services incorporating such information. The sender of any communications to this website or otherwise to the owners of this site shall be responsible for the content and information contained therein, including its truthfulness and accuracy.

Certain statements in this site constitute "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and other similar expressions, which are predictions of or indicate future events and trends and which do not relate to historical matters, identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. Although forward-looking statements reflect the good faith beliefs of Celldex's management, reliance should not be placed on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievement of Celldex to differ materially from anticipated future results, performance or achievements expressed or implied by such forward-looking statements. We expressly disclaim any responsibility to update forward-looking statements. Celldex undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise on or after the date of posting of the information on this website.

ALL CONTENT ON THIS WEBSITE IS PROVIDED TO YOU ON AN "AS IS" and "AS AVAILABLE" BASIS WITHOUT WARRANTY OF ANY KIND EITHER EXPRESS OR IMPLIED INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, AND NON-INFRINGEMENT. CELLDEX MAKES NO WARRANTY AS TO THE ACCURACY, COMPLETENESS, CURRENCY, OR RELIABILITY OF ANY CONTENT AVAILABLE THROUGH THIS WEBSITE. YOU ARE RESPONSIBLE FOR VERIFYING ANY INFORMATION BEFORE RELYING ON IT. USE OF THE WEBSITE AND THE CONTENT AVAILABLE ON THE WEBSITE IS AT YOUR SOLE RISK. CELLDEX MAKES NO REPRESENTATIONS OR WARRANTIES THAT USE OF THE WEBSITE WILL BE UNINTERRUPTED OR ERROR-FREE. YOU ARE RESPONSIBLE FOR TAKING ALL NECESSARY PRECAUTIONS TO ENSURE THAT ANY CONTENT YOU OBTAIN FROM THE WEBSITE IS FREE OF VIRUSES.

The above exclusions may not apply in jurisdictions that do not allow the exclusion of certain implied warranties.

YOUR USE OF THE WEBSITE OR ANY CONTENT ON THE WEBSITE IS AT YOUR OWN RISK. CELLDEX SPECIFICALLY DISCLAIMS ANY LIABILITY, WHETHER BASED IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH ACCESS TO OR USE OF THE WEBSITE, EVEN IF CELLDEX HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES INCLUDING, BUT NOT LIMITED TO, RELIANCE BY ANY PARTY ON ANY CONTENT OBTAINED THROUGH THE USE OF THE WEBSITE OR THAT ARISES IN CONNECTION WITH MISTAKES OR OMISSIONS IN OR DELAYS IN TRANSMISSION OF INFORMATION TO OR FROM THE USER, INTERRUPTIONS IN TELECOMMUNICATIONS CONNECTIONS TO THE WEBSITE OR VIRUSES, WHETHER CAUSED IN WHOLE OR IN PART BY NEGLIGENCE, ACTS OF GOD, WAR, TERRORISM, TELECOMMUNICATIONS FAILURE, THEFT OR DESTRUCTION OF OR UNAUTHORIZED ACCESS TO THE WEBSITE OR RELATED INFORMATION OR PROGRAMS.